<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04752865</url>
  </required_header>
  <id_info>
    <org_study_id>TR_NACT_OV/17</org_study_id>
    <nct_id>NCT04752865</nct_id>
  </id_info>
  <brief_title>Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer</brief_title>
  <official_title>Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hellenic Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      EFFECTS OF CYTOTOXIC CHEMOTHERAPY AND PARP INHIBITION ON THE GENOMIC CONTEXTURE OF OVARIAN&#xD;
      CANCER: TR_NACT_OV/17 In order to approach the above open questions, ultimately aiming in&#xD;
      understanding the effects of cancer drugs on tumor biology and hence in selecting the proper&#xD;
      drugs for the patients in the context of Precision Medicine, the objective of this study is&#xD;
      to study the genomic characteristics of ovarian tumors before and after treatment with&#xD;
      classic neoadjuvant chemotherapy (NACT) and with the more recently approved PARP inhibitor&#xD;
      olaparib.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2018</start_date>
  <completion_date type="Anticipated">December 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 29, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>assesment of genomic characteristics of ovarian tumors at the diagnosis</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>assesment of genomic characteristics of ovarian tumors after treatment with neoadjuvant platinum-based chemotherapy</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ovarian Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      FFPE tissues will be histologically reviewed for tumor presence and evaluated for tumor cell&#xD;
      content (TCC%) and adequacy for genotyping, tumor lymphocytic infiltrates (TILs) and further&#xD;
      morphologic features (presence of intraepithelial lymphocytes, micro- and macro-necrosis,&#xD;
      hemorrhagic infiltrates, specific and heterogeneous morphologic patterns) that will be&#xD;
      recorded in detail.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        women with ovarian cancer eligible for neoadjuvant chemotherapy. The investigators examined&#xD;
        changes in tissue molecular profile. The investigators examine tissue molecular profile at&#xD;
        diagnosis and after the end of neoadjuvant chemotherapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ovarian cancer eligible for neoadjuvant chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adamantia Nikolaidi</last_name>
    <role>Study Chair</role>
    <affiliation>HECOG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adamantia Nikolaidi, MD</last_name>
    <phone>00302106912520</phone>
    <phone_ext>12</phone_ext>
    <email>hecogoff@otenet.gr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Moschoni</last_name>
    <phone>00302106912520</phone>
    <phone_ext>12</phone_ext>
    <email>m_moschoni@hecog.ondsl.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Adamantia Nikolaidi</name>
      <address>
        <city>Athens</city>
        <zip>11524</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Moschoni</last_name>
      <phone>00302106912520</phone>
      <phone_ext>12</phone_ext>
      <email>hecogoff@otenet.gr</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

